有关其他公司更新,请参阅公告和通告部分。

- 更多新闻稿 -

3SBio Inc. Selected as a Constituent of the MSCI China Index

SHENYANG, China, May 13, 2016 /PRNewswire/ -- 3SBio Inc., (HKEX:1530) ("3SBio") today announced that according to an announcement posted on the MSCI Inc. website on May 12, 2016, 3SBio will be added as a constituent to the MSCI China Index after the market closes on May 31, 2016.

"We are pleased that 3SBio has been included in the MSCI China Index and believe it will enhance 3SBio's profile in the international investment community," commented Dr. Jing Lou, chairman and chief executive officer of 3SBio.

About 3SBio

3SBio is a leading biotechnology company in the People's Republic of China (the "PRC") founded in 1993.  As a pioneer in the PRC biotechnology industry, 3SBio has extensive expertise in developing, manufacturing and marketing biopharmaceuticals. Three core products, TPIAO, Yisaipu and EPIAO are market leaders in the PRC. TPIAO is the only commercialized recombinant human thrombopoietin (rhTPO) product in the world. Yisaipu, a recombinant human tumor necrosis factor-α receptor II (TNFR) – IgG Fc fusion protein for the treatment of rheumatoid arthritis is the industry leader with a market share in excess of 60% according to IMS data. EPIAO, a recombinant human erythropoietin (rhEPO) product, together with the other rhEPO product acquired recently, SEPO, is the dominant market leader in the rhEPO market, according to IMS data. In addition, 3SBio has more than 50 other products in the oncology, rheumatology, nephrology, dermatology and other therapeutic areas. 3SBio is focused on building an innovative product pipeline, with over 20 National Class 1 candidates under development.

3SBio maintains manufacturing facilities in Shenyang, Shanghai, Hangzhou and Shenzhen, as well as in Como, Italy, with a total of over 3,000 employees. A state-of-the-art mammalian biological manufacturing facility in Shenyang is the first and only rhEPO facility in the PRC that conforms to both Chinese and European pharmacopeia standards. Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd., ("Guojian") is a leading company in the PRC's antibody sector that develops and commercializes new biologic therapies targeting cancer and autoimmune diseases. Guojian's antibody manufacturing capacity is among the largest in the industry in the PRC. Zhejiang Wansheng Pharmaceutical Co., Ltd, specializes in R&D, production and sales of chemically synthesized pharmaceuticals.

3SBio's pharmaceutical products are marketed and sold in 32 provinces, autonomous regions and special municipalities in the PRC, as well as a number of foreign countries and regions. 3SBio's nationwide sales and distribution network covers over 4,000 hospitals and medical institutions in the PRC. 3SBio is also actively pursuing international expansion through acquisition, licensing and partnerships.

Please visit www.3sbio.com for additional information.

Contacts:

Rachel You
Financial Controller
3SBio Inc.
Tel: +852 2593-1243
Email: youfei@3sbio.com  

Tom Folinsbee
Director, Corporate Development
3SBio Inc.
Tel: +852 2593-1243
Email: tomfolinsbee@3sbio.com